12:00 AM
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

THV01-1: Phase I/II start

By year end, Theravectys will begin the double-blind, placebo-controlled, European Phase I/II THV01 trial to evaluate 3 dose levels of intramuscular THV01-1 followed by THV01-2 given 8 weeks apart in...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >